Targeted therapy venetoclax improving acute myeloid leukemia treatment options
Targeted therapies are designed to work against specific vulnerabilities in a cancer cell.
The targeted therapy drug venetoclax is designed to block the function of the B-cell lymphoma-2 (Bcl-2) protein, which normally works to prevent cell death.
Short telomere length predicts nonrelapse mortality after stem cell transplantation for myelodysplastic syndrome
Key Points
Recipient telomere length is independently associated with overall survival and NRM after transplantation for MDS.
Stem Cell Transplants for Leukemia
Stem cell transplantation (SCT) offers many people with blood and bone marrow cancers hope for a potential cure. More than 17,500 stem cell transplants are performed in the U.S. annually.
Real-World Treatment Patterns, FLT3 Testing, and Outcomes in AML
Outcomes of Adding a Fourth Chemotherapy Course in AML
Eprenetapopt (APR-246) and Azacitidine in TP53-Mutant Myelodysplastic Syndromes
PURPOSE
Clinical characteristics and outcomes of COVID-19 in haematopoietic stem-cell transplantation recipients: an observational cohort study
Background
Haematopoietic stem-cell transplantation (HSCT) recipients are considered at high risk of poor outcomes after COVID-19 on the basis of their immunosuppressed status, but data from large studies in HSCT recipients are lacking. This study describes the characteristics and outcomes of HSCT recipients after developing COVID-19.
Is blood transfusion safe during the COVID-19 pandemic?
Journal Title:
Future Science OA
Original Publication Date:
Sep 2020
The rapid spread of the coronavirus disease 2019 (COVID-19) pandemic has challenged healthcare systems to re-organize the management of patients in a short period. The causative pathogen of this pandemic is severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), one of seven coronaviruses that can be found in humans. It is a rapidly mutating, enveloped, ssRNA, beta-coronavirus. The initial reports published after the pandemic spread showed a transmissibility rate of 2.2 and possibly low values of dispersion.
Bone Marrow Disease(s):